AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Quinn William P. sold $58K of BOLT

Quinn William P. (President, CEO and CFO) sold 17,566 shares of Bolt Biotherapeutics, Inc. (BOLT) at an average of $3.32 ($3.24–$3.77) across 3 trades over 2026-09-16 to 2026-09-18.

Original reporting
SEC EDGAR · Quinn William P.
Published Sep 21, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The sale is modest and does not suggest a shift in company strategy.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results not disclosed; sale may be unrelated to fundamentals.

Relevance 3/10Novelty 4/10Timing: Filed Sep 21 2026 (Form 4)

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

CEO Quinn William P. sold 17,566 shares for $58,402, reducing his stake to 25,384 shares.

Expected impact

Minimal short-term price pressure, likely negligible.

Evidence & confidence

The sale amount is small relative to market cap and typical insider activity; no change in control.

Market effects

Sector

No broader sector impact; biotech insider sales are routine.

Regional

Limited to U.S. biotech investors.

Global

Low

Counterpoint

What could challenge this read

If the CEO is reducing exposure, it could signal concerns about upcoming data.

Key entities

  • company
    Bolt Biotherapeutics, Inc.

    NASDAQ-listed biotech developing gene therapies.

  • person
    Quinn William P.

    President, CEO and CFO of Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K